Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-071560
Filing Date
2025-05-14
Accepted
2025-05-14 16:50:30
Documents
64
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ck0001774857-20250331.htm   iXBRL 10-Q 2135845
2 EX-31.1 ck0001774857-ex31_1.htm EX-31.1 17569
3 EX-31.2 ck0001774857-ex31_2.htm EX-31.2 17545
4 EX-32.1 ck0001774857-ex32_1.htm EX-32.1 12400
5 EX-32.2 ck0001774857-ex32_2.htm EX-32.2 12157
6 GRAPHIC img180516736_0.jpg GRAPHIC 746726
  Complete submission text file 0000950170-25-071560.txt   8676235

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ck0001774857-20250331.xsd EX-101.SCH 821519
67 EXTRACTED XBRL INSTANCE DOCUMENT ck0001774857-20250331_htm.xml XML 962072
Mailing Address 4370 LA JOLLA VILLAGE DRIVE SUITE 1050 SAN DIEGO CA 92122
Business Address 4370 LA JOLLA VILLAGE DRIVE SUITE 1050 SAN DIEGO CA 92122 (858) 225-7696
Aardvark Therapeutics, Inc. (Filer) CIK: 0001774857 (see all company filings)

EIN.: 821606367 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42513 | Film No.: 25946696
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)